

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

WU-KONG28 Study

- Sunvozertinib, an oral *EGFR* exon 20 insertion targeting inhibitor, demonstrates robust improved clinical efficacy compared to chemotherapy alone (response rates, duration of response, and median progression-free survival) in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with an *EGFR* exon 20 insertion mutation. Survival data continues to mature with no current overall survival difference seen.
- Rash and diarrhea are key adverse events to monitor for with patients receiving sunvozertinib throughout treatment. Appropriate awareness, education, and monitoring/management strategies, including prophylactic use of topical treatments and antidiarrheal agents are vital to effective management and maintaining patients on therapy.